1. 167: A phase I/II trial of combination nab-paclitaxel and nintedanib or nab-paclitaxel and placebo in relapsed NSCLC adenocarcinoma (N3). (January 2017) Authors: Tokaca, N.; Espinasse, A.; Petruckevitch, A.; Ellis, S.; Yousaf, N.; Bhosle, J.; O'Brien, M.; Popat, S. Journal: Lung cancer Issue: Volume 103(2017)Supplement 1 Page Start: S77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 33: Adequacy of image-guided rebiopsies for molecular retesting in advanced NSCLC: a single centre experience. (January 2017) Authors: Tokaca, N.; Barth, S.; O'Brien, M.; Bhosle, J.; Fotiadis, N.; Wotherspoon, A.; Thompson, L.; Popat, S. Journal: Lung cancer Issue: Volume 103(2017)Supplement 1 Page Start: S15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 69: Outcomes with nintedanib and docetaxel in patients with relapsed NSCLC adenocarcinoma treated within the UK Nintedanib Individual Patient Supply programme. (January 2017) Authors: Tokaca, N.; Crawford, M.S.; Greystoke, A.; Appel, W.; Lal, R.; Steele, N.; Ali, C.; Bezecny, P.; Fernando, S.; Karapanagiotou, E.; Skailes, G.; Dorey, N.; Harrow, S.; Bhosle, J.; Khan, O.; Newsom-Davis, T.; Spicer, J.; Toy, L.; O'Brien, M.; Gunapala, R. Journal: Lung cancer Issue: Volume 103(2017)Supplement 1 Page Start: S32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 87P Infliximab use in patients with checkpoint inhibitor toxicities: A tertiary centre experience. (December 2022) Authors: Zhang, S.H.; Cartwright, E.; Mullings, S.; Ferro Lopez, L.F.; Cunningham, D.; Chau, I.; Starling, N.; Popat, S.; O'Brien, M.E.R.; Bhosle, J.; Minchom, A.R.; Davidson, M.; Tokaca, N.; Lalondrelle, S.; Pickering, L.M.; Furness, A.; Turajlic, S.; Larkin, J.; José, R.; Young, K. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Real-world outcomes with pembrolizumab in patients with treatment-naive advanced/metastatic NSCLC in the UK: multicentre retrospective observational study. (January 2019) Authors: Tokaca, N.; Gomes, F.; Lau, S.; Jackson, A.; Gradwell, M.; Gyi, M.; Reinius, M.; Valentine, E.; Winn, E.; Bhosle, J.; O'Brien, M.; Yousaf, N.; Blackhall, F.; Gilligan, D.; Treece, S.; Yip, K.; Geldart, T.; Baluch, S.; Gulliford, T.; Muthuramalingam, S. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The ALK project: a real-world national network and database. (January 2019) Authors: Gomes, F.; Yip, K.; Tokaca, N.; Greystoke, A.; Escriu, C.; Conibear, J.; Ghosh, S.; Doherty, G.J.; Funingana, I.; Ahmad, T.; Ahmed, S.; Cox, R.A.; Newsom-Davis, T.; Mills, H.; Shah, R.; Dorey, N.; Harle, A.; Dancey, G.; Baijal, S.; Geldart, T. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗